Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Dec 31;19(1):2196893.
doi: 10.1080/21645515.2023.2196893. Epub 2023 Apr 14.

A systematic review and meta-analysis of the seroconversion rates and adverse effects of COVID-19 mRNA vaccine and COVID-19 viral vector vaccine in kidney transplant recipient patients

Sikai Chen  1 , Wenxin Wei  2 , Fengyu Huang  1 , Jing Wang  1 , Xingyu Li  1 , Zhixin Geng  1 , Feng Gao  1 , Taiwei Dong  1 , Peifeng Wei  1   3 , Xinbo Yang  4 , Feng Miao  3
Affiliations
Meta-Analysis

A systematic review and meta-analysis of the seroconversion rates and adverse effects of COVID-19 mRNA vaccine and COVID-19 viral vector vaccine in kidney transplant recipient patients

Sikai Chen et al. Hum Vaccin Immunother. .

Abstract

Patients received kidney transplantation (KTR) have a low seroconversion rate after vaccination. Our objective was to compare the seroconversion rates and adverse effects of additional different vaccinations in KTR patients in existing studies. Databases such as PubMed, Cochrane Library, Web of Science, Embase, ClinicalTrials.gov and others. Three high-quality RCT were included and showed no statistical difference in seroconversion rates between the two vaccines (RR = 0.93[0.76,1.13]). There was no statistical difference in seroconversion rates between the sexes, for men (RR = 0.93[0.69,1.25]) and women (RR = 0.91[0.62,1.33]). Among the adverse effects there was no statistically significant difference in fever (RR = 1.06[0.44,2.57]), while for injection site pain there was a statistically significant difference (RR = 1.14[1.18,1.84]). There was no significant difference in seroconversion rates in patients with KTR who received the two additional vaccines. Patients injected with the viral vector vaccine were less painful than those injected with the mRNA vaccine.

Keywords: COVID-19; adverse effects; kidney transplant recipient; mRNA vaccine; seroconversion rate; viral vector vaccine.

PubMed Disclaimer

Conflict of interest statement

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1.
Figure 1.
PRISMA flowchart of literature search.
Figure 2.
Figure 2.
Quality evaluation of included literature.
Figure 3.
Figure 3.
Seroconversion rates of the two vaccines.
Figure 4.
Figure 4.
Seroconversion rates of the two vaccines between different genders.
Figure 5.
Figure 5.
Comparison of injection site pain between the two vaccines.
Figure 6.
Figure 6.
Comparison of patient fever between the two vaccines.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lee A, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, Tay SH, Teo CB, Tan BK, Chan YH, et al. Efficacy of COVID-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376:e068632. doi:10.1136/bmj-2021-068632. - DOI - PMC - PubMed
    1. Han X, Xu P, Ye Q.. Analysis of COVID-19 vaccines: types, thoughts, and application. J Clin Lab Anal. 2021;35(9):e23937. doi:10.1002/jcla.23937. - DOI - PMC - PubMed
    1. Park H, Park MS, Seok JH, You J, Kim J, Kim J, Park M-S.. Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines. J Microbiol. 2022;60(3):308–8. doi:10.1007/s12275-022-1598-x. - DOI - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–15. doi:10.1056/NEJMoa2034577. - DOI - PMC - PubMed
    1. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H, Spiessens B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N Engl J Med. 2021;384(23):2187–201. doi:10.1056/NEJMoa2101544. - DOI - PMC - PubMed

Publication types